Abstract
Patients with unstable angina pectoris/non-ST-elevation myocardial infarction (NSTEMI) should be treated with dual antiplatelet therapy with the use of aspirin plus either clopidogrel, prasugrel, or ticagrelor depending on the clinical circumstances as discussed in this article.
If ticagrelor is used, the dose of aspirin must not exceed 100 mg daily. Prasugrel must not be used in patients with a history of stroke or transient ischemic attack. Platelet glycoprotein IIb/IIIa inhibitors should not be used as part of triple antiplatelet drug therapy if there is an increased risk for bleeding or in non-high-risk patients such as those with a normal baseline cardiac troponin level, nondiabetics, and those aged 75 years and older in whom potential benefit may be significantly offset by the potential risk of bleeding. Clinical trial data in patients with acute coronary syndromes do not support the use of intravenous cangrelor or oral voraxapar in the treatment of these patients.
Keywords: Acute coronary syndromes, unstable angina pectoris, non-ST-elevation myocardial infarction, aspirin, clopidogrel, prasugrel, ticagrelor, glycoprotein IIb/IIIa inhibitors, cangrelor, voraxapar.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Use of Antiplatelet Drugs in the Treatment of Acute Coronary Syndromes
Volume: 13 Issue: 2
Author(s): Wilbert S. Aronow
Affiliation:
Keywords: Acute coronary syndromes, unstable angina pectoris, non-ST-elevation myocardial infarction, aspirin, clopidogrel, prasugrel, ticagrelor, glycoprotein IIb/IIIa inhibitors, cangrelor, voraxapar.
Abstract: Patients with unstable angina pectoris/non-ST-elevation myocardial infarction (NSTEMI) should be treated with dual antiplatelet therapy with the use of aspirin plus either clopidogrel, prasugrel, or ticagrelor depending on the clinical circumstances as discussed in this article.
If ticagrelor is used, the dose of aspirin must not exceed 100 mg daily. Prasugrel must not be used in patients with a history of stroke or transient ischemic attack. Platelet glycoprotein IIb/IIIa inhibitors should not be used as part of triple antiplatelet drug therapy if there is an increased risk for bleeding or in non-high-risk patients such as those with a normal baseline cardiac troponin level, nondiabetics, and those aged 75 years and older in whom potential benefit may be significantly offset by the potential risk of bleeding. Clinical trial data in patients with acute coronary syndromes do not support the use of intravenous cangrelor or oral voraxapar in the treatment of these patients.
Export Options
About this article
Cite this article as:
Aronow S. Wilbert, Use of Antiplatelet Drugs in the Treatment of Acute Coronary Syndromes, Cardiovascular & Hematological Disorders-Drug Targets 2013; 13 (2) . https://dx.doi.org/10.2174/1871529X11313020008
DOI https://dx.doi.org/10.2174/1871529X11313020008 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Identification of Inflammatory, Metabolic, and Cell Survival Pathways Contributing to Cerebral Small Vessel Disease by Postmortem Gene Expression Microarray
Current Neurovascular Research MicroRNA-155 Functions as a Negative Regulator of RhoA Signaling in TGF-β-induced Endothelial to Mesenchymal Transition
MicroRNA Thrombomodulin Links Coagulation to Inflammation and Immunity
Current Drug Targets Lipid Nanoparticles as Vehicles for Macromolecules: Nucleic Acids and Peptides
Recent Patents on Drug Delivery & Formulation Nitric Oxide and its Antithrombotic Action in the Cardiovascular System
Current Drug Targets - Cardiovascular & Hematological Disorders Recent Progress in Therapeutic and Diagnostic Applications of Lanthanides
Mini-Reviews in Medicinal Chemistry Serpinins: Role in Granule Biogenesis, Inhibition of Cell Death and Cardiac Function
Current Medicinal Chemistry Integrin Signaling Networks in the Pathobiology of Vascular Smooth Muscle Cells
Vascular Disease Prevention (Discontinued) L-carnitine: Searching for New Therapeutic Strategy for Sepsis Management
Current Medicinal Chemistry Vascular C-Reactive Protein in the Pathogenesis of Coronary Artery Disease:Role of Vascular Inflammation and Oxidative Stress
Cardiovascular & Hematological Disorders-Drug Targets Gender Differences in Non-Obstructive Coronary Artery Disease
Current Pharmaceutical Design Endothelial Dysfunction in Heart Failure: Mechanisms and Therapeutic Approaches
Current Vascular Pharmacology The Role of Annexin A1 and Formyl Peptide Receptor 2/3 Signaling in Chronic Corticosterone-Induced Depression-Like behaviors and Impairment in Hippocampal-Dependent Memory
CNS & Neurological Disorders - Drug Targets Acute Coronary Syndromes in Patients with Atrial Fibrillation and Heart Failure. Could Novel Oral Anticoagulants be the Solution of the Optimal Antithrombotic Therapy Puzzle?
Cardiovascular & Hematological Agents in Medicinal Chemistry Blocking Leukocyte Rolling: Does it have a Role in Disease Prevention?
Vascular Disease Prevention (Discontinued) Endoplasmic Reticulum Stress and Atherosclerosis
Current Hypertension Reviews Ca2+ Signalling in Damaged Endothelium and Arterial Remodelling: Do Connexin Hemichannels Provide a Suitable Target to Prevent In-stent Restenosis?
Current Drug Therapy Inflammatory Markers in Essential Hypertension: Potential Clinical Implications
Current Vascular Pharmacology Nitric Oxide: State of the Art in Drug Design
Current Medicinal Chemistry Unfolded Protein Response as a Therapeutic Target in Cardiovascular Disease
Current Topics in Medicinal Chemistry